Supartz Injection denied? Start your appeal.
Start with the reason on your denial notice. Check your plan’s appeal route, then gather the records that answer the specific coverage rule.
No account or payment to check your route. You confirm the plan facts; published review outcomes do not predict your result.
Free evidence checklist for knee osteoarthritis
What to gather for a knee injection appeal
Use the published decisions to ask better questions, then answer the exact rule in your denial. Bring this checklist to your treating clinician; it does not tell you which treatment to choose.
Download blank checklist (.txt)- The denial and the applicable rule. Keep the complete notice, notice date, filing deadline, recipient, and the exact plan policy or criterion cited. Ask which benefit covers the injection and whether the dispute is medical necessity, a preferred product, repeat timing, or a billing issue.
- Diagnosis, knee, and functional limits. Ask the clinician to identify the affected knee, diagnosis, relevant imaging report, and how pain limits walking, standing, or other daily activities. Do not infer a diagnosis from pain alone.
- Conservative care already tried. List each treatment, dates, duration, response, and adverse effects. Include non-drug approaches and medicines where relevant. Ask the clinician to explain any contraindication instead of treating a contraindicated therapy as a required trial.
- Why this product and this request. Ask the prescriber to answer the actual denial criterion, explain the individual rationale, and check the requested dose and schedule against current product labeling. Approval of one hyaluronic-acid product does not establish coverage for every product.
- If this is a repeat series. Record prior injection dates, which knee was treated, measurable pain and function changes, when symptoms returned, and why the timing satisfies the applicable policy. A first series and a repeat series can have different criteria.
- A complete submission record. Match each disputed criterion to an attachment. Confirm the governing appeal route, send it using the notice instructions, and keep the submission receipt. Ask the clinician about an urgent review if waiting could seriously harm health.
Coverage criteria and clinical guidance are different
For example, Medicare LCD L39260 requires documented symptomatic knee osteoarthritis, radiographic support, a qualifying conservative-care history, and other criteria. Repeat treatment has separate requirements, including a prior response and a minimum interval. This is a local policy: verify the contractor, service date, and complete rule before relying on it.
AAOS does not recommend hyaluronic-acid injections for routine knee osteoarthritis use. Favorable historical reviews do not erase that limitation. Ask the clinician to explain the individual rationale and address the plan's criteria. For Monovisc, consult the FDA approval record and current labeling; FDA approval is not a coverage guarantee.
U.S. self-help preparation for knee osteoarthritis injection denials; not medical or legal advice. The historical California review rate is not your chance of success. L39260 is a local Medicare policy, not a nationwide rule for every plan. Confirm contractor jurisdiction, service date, and the policy in your notice. Clinical guidance and FDA labeling do not guarantee insurance coverage. Sources reviewed 2026-09-05.
- FDA: Monovisc approval record and labeling
- CMS: local coverage determination L39260
- AAOS: knee osteoarthritis clinical guideline
The download is a blank, printable worksheet. Fill it in privately; nothing you write in the downloaded file is sent to Coverage Rights.
In the California DMHC record, independent physician reviewers decided 83 published external-review cases involving Supartz Injectionand overturned the plan’s denial in 73.5%. That is a historical result among cases that reached this program, not a forecast for an individual appeal.
By condition
| Condition | Decisions | Overturned |
|---|---|---|
| Osteoarthritis Of The Knee | 38 | 73.7% |
| Knee Osteoarthritis | 17 | 64.7% |
What the insurer actually argued
| Reason given | Decisions | Overturned |
|---|---|---|
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 79 | 75.9% |
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 4 | 25% |
What the reviewers wrote
Where the denial was overturned
Nature of Statutory Criteria/Case Summary:The patient is a male with bilateral knee osteoarthritis. The patient had increasing pain in both knees secondary to his osteoarthritis. The patient desired to undergo another injection series with Supartz. He had continued swelling, giving way sensations, and pain. A bilateral knee examination documented good range of motion, crepitus with range of motion, medial and lateral joint line tenderness, an intra-articular effusion, no instability, and no obvious deformities. He was reporting 100% improvement with the injections to date. He had good range of motion with crepitus. One additional Supartz injection was recommended to the right knee. The patient has requested coverage for Supartz injections. The Health Plan denied the request and reported that the requested services are not medically necessary for the treatment of this patient.
Nature of Statutory Criteria/Case Summary: This patient is a 55-year-old female with a diagnosis of osteoarthritis, hypertension and diabetes. A review of records documented the patient had a history of bilateral knee pain. The records noted constant moderate bilateral knee pain, right greater than left. Her pain was worse with motion and walking, and better with rest. The diagnosis was primary osteoarthritis of both knees. The patient had tried and failed conservative options, including corticosteroid injections and anti-inflammatory medication. The treatment plan recommended Supartz series. The patient has requested authorization and coverage for Supartz injections for both knees. The Health Plan has denied this request and reported that the requested services are not medically necessary for the treatment of this patient.
Where the denial was upheld
Nature of Statutory Criteria/Case Summary: An enrollee has requested Supartz injections for treatment of the enrollee’s hip pain. Findings: The physician reviewer found that the review of the submitted documentation and relevant literature fails to demonstrate the medical necessity for the requested medication. There is limited peer-reviewed literature supporting Supartz injections for the treatment of osteoarthritis of the hip. Migliore and colleagues noted that sodium hyaluronate ultrasound guided injection seemed to delay total hip replacement in the context of overall management of symptomatic hip osteoarthritis patients.
Nature of Statutory Criteria/Case Summary: An enrollee has requested Flector (diclofenac epolamine) patches and bilateral knee Supartz injections for treatment of her medical conditions. Findings: The physician reviewer found that the Flector patch and bilateral knee Supartz injections are not medically necessary for treatment of the patient’s medical conditions. Flector is a topical non-steroidal anti-inflammatory drug (NSAID). Researchers performed a systematic review to address and summarize the evidence of effectiveness and safety in topical NSAIDs. The authors concluded that topical NSAIDs may vary significantly in their absorption kinetics and pharmacodynamic effects, based on the formulation chosen. In acute and chronic low back pain, widespread musculoskeletal pain and in peripheral neuropathic pain syndromes, the current evidence does not support the use of topical NSAIDs.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California external-review outcomes. Other state and federal programs have different eligibility rules, processes, and current availability; the rates here do not transfer to those programs or predict an individual result. Excerpts are quoted verbatim from the public record and describe this treatment generally, not any individual case.
These outcomes describe eligible cases completed through California DMHC’s Independent Medical Review program. They do not estimate the chance that an internal appeal, an external review in another jurisdiction, or your individual case will succeed. Use the record to identify evidence patterns involving Supartz Injection, then check the rights and deadlines that apply to your plan.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · AGGREGATES + DEIDENTIFIED DECISION EXCERPTS/REFERENCE IDS · METHODOLOGY